miR-15a and miR-24-1 as putative prognostic microRNA signatures for pediatric pilocytic astrocytomas and ependymomas
- 153 Downloads
In the current setting, we attempted to verify and validate miRNA candidates relevant to pediatric primary brain tumor progression and outcome, in order to provide data regarding the identification of novel prognostic biomarkers. Overall, 26 resected brain tumors were studied from children diagnosed with pilocytic astrocytomas (PAs) (n = 19) and ependymomas (EPs) (n = 7). As controls, deceased children who underwent autopsy and were not present with any brain malignancy were used. The experimental approach included microarrays covering 1211 miRNAs. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to validate the expression profiles of miR-15a and miR-24-1. The multiparameter analyses were performed with MATLAB. Matching differentially expressed miRNAs were detected in both PAs and EPs, following distinct comparisons with the control cohort; however, in several cases, they exhibited tissue-specific expression profiles. On correlations between miRNA expression and EP progression or outcome, miR-15a and miR-24-1 were found upregulated in EP relapsed and EP deceased cases when compared to EP clinical remission cases and EP survivors, respectively. Taken together, following several distinct associations between miRNA expression and diverse clinical parameters, the current study repeatedly highlighted miR-15a and miR-24-1 as candidate oncogenic molecules associated with inferior prognosis in children diagnosed with ependymoma.
KeywordsPilocytic astrocytomas Ependymomas MicroRNA microarrays Prognosis Biomarkers
Area under the curve
Central nervous system
Quantitative real-time polymerase chain reaction
Receiver operating characteristic curves
World Health Organization
MB conceived and designed the study, performed all experiments, evaluated and interpreted data analyses, and drafted the manuscript. GIL performed all data analyses and participated in interpretation of data analyses and in drafting the manuscript. GK assisted in microarrays performance. SAP performed resections of the postmortem specimens. AL performed qRT-PCR experiments. KS performed tumor diagnosis. GS performed all tumor resections. FTS treated patients. AK, FTS, MT, KTS, and EK participated in the coordination and supervision of the study. All authors approved the final manuscript.
Compliance with ethical standards
Conflict of interests
The authors declare no competing financial or nonfinancial interests.
- 12.Agarwal V, Bell GW, Nam JW, Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. eLife 2015;4Google Scholar
- 19.Kramer K, Wu J, Crowe DL: Tumor suppressor control of the cancer stem cell niche. Oncogene 2015Google Scholar
- 29.Xiao G, Tang H, Wei W, Li J, Ji L, Ge J. Aberrant expression of microRNA-15a and microRNA-16 synergistically associates with tumor progression and prognosis in patients with colorectal cancer. Gastroenterology Res Pract. 2014;2014:364549.Google Scholar
- 33.Sand M, Skrygan M, Sand D, Georgas D, Gambichler T, Hahn SA, et al. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2013;351:85–98.CrossRefPubMedGoogle Scholar
- 38.Zhao Z, Qin L, Li S: miR-411 contributes the cell proliferation of lung cancer by targeting FOXo1. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 2015Google Scholar